A New Exit for the Brain’s Waste? Alzheimer’s Lymphatic-Bypass Surgery Moves Toward Multinational Trials

Several videos showing patients appearing dramatically different before and after surgery have led to a microsurgical procedure originally used to improve lymphatic drainage being rapidly embraced in China as a potential new treatment for Alzheimer’s disease. That enthusiasm is now moving beyond scattered cases and testimonial-style narratives into regulated trials in the United States, Singapore, and elsewhere. The real question is not only whether patients improve in the short term, but whether the surgery can safely, durably, and reproducibly alter the course of the disease.

This “cervical lymphatic–venous bypass surgery” connects deep cervical lymph nodes or tiny lymphatic vessels to nearby veins in an attempt to create a less obstructed outlet for fluid and metabolic waste from the brain. Its theoretical basis comes from recent research into the meningeal lymphatic and glymphatic systems: these pathways may be involved in clearing substances such as amyloid and tau proteins, and their function may deteriorate with aging or disease. However, between “impaired drainage may contribute to disease progression” and “a cervical bypass can improve dementia” lies a biological chain that has yet to be adequately validated.

The early-stage U.S. REMIND feasibility study uses the Symani robotic microsurgery platform to perform this type of reconstruction and enrolls patients with Alzheimer’s disease who have lymphatic abnormalities. After reviewing 30-day safety data from the first participants, the U.S. Food and Drug Administration approved a supplemental investigational device exemption application, allowing enrollment to expand from a maximum of 5 people to the full study population of 15. This decision means that the study may continue; it does not mean that the FDA has determined the surgery to be effective. The developer has also explicitly stated that the safety and efficacy of the system for lymphatic reconstruction in brain disease have not been established.

Changi General Hospital in Singapore, meanwhile, has launched the CLyVeB-AD-1 proof-of-concept study, registered on ClinicalTrials.gov as NCT06965062. At the time of the hospital’s announcement, 4 patients aged 61 to 73 with biomarker-confirmed mild to moderate Alzheimer’s disease had undergone surgery. The study tracks cognition, quality of life, caregiver burden, and indicators of neurodegeneration and lymphatic function in blood and cerebrospinal fluid. The hospital reported changes in some clinical scales and cerebrospinal fluid markers, but these findings come from preliminary observations in an extremely small study with no control group and cannot rule out measurement variability, care interventions, or expectation effects.

This is also the focus of the controversy. Although dramatic short-term improvements in Chinese cases have drawn the attention of more patients and physicians, they cannot replace randomized controls, blinded assessments, and long-term follow-up. Cognition and behavior in patients with Alzheimer’s disease naturally fluctuate, and the care environment may also change before and after surgery. Without an appropriate comparison group, it is difficult to determine the true cause even if imaging, scale scores, or biomarkers change in parallel. Moreover, this is an invasive operation, so evaluation criteria cannot focus solely on whether improvement occurs; they must also clarify complications, the durability of any effects, and which patients may bear the risks without benefiting.

At a minimum, the multinational trials return the question to a testable path through standardized enrollment, prespecified endpoints, and ongoing safety monitoring. Even if early studies demonstrate that the technique is feasible, the next step will still require larger trials with control groups to determine whether clinical improvements exceed placebo effects and are consistent with the mechanism of clearing waste from the brain. Until such evidence is available, lymphatic-bypass surgery should be understood as a research hypothesis awaiting validation, not as a treatment already capable of reversing Alzheimer’s disease.